March 26, 2008 - Sanofi-aventis announced that the National Institute for Health and Clinical Excellence (NICE) has issued its Final Appraisal Determination (FAD) on Acomplia® (rimonabant) which proposes guidance recommending the use of the drug in England and Wales, within its licensed indications, as an adjunct to diet and exercise for adults who are obese or overweight and who have had an inadequate response to, are intolerant of, or are contraindicated to other antiobesity agents that have previously been reviewed by NICE.Sanofi-aventis is delighted that the Institute has recommended that Acomplia® should be made available for the management of obese and overweight National Health Service (NHS) patients, and believes that Acomplia® is a valuable addition to the limited treatment options currently available... [PDF] Sanofi-aventis' Press Release - [PDF] Communiqué de Presse Sanofi-aventis -
